Core Viewpoint - The company, Oppein Home, announced the approval of a plan to utilize idle raised funds for cash management, with a total limit of up to RMB 350 million, effective from August 19, 2025, to August 18, 2026 [2]. Group 1 - The company held its 26th meeting of the 4th Board of Directors and the 17th meeting of the 4th Supervisory Board on August 8, 2025 [2]. - The resolution allows the company to manage temporarily idle raised funds for cash management purposes [2]. - The decision is part of the company's strategy to optimize the use of its financial resources [2].

Group 1 - The company announced the approval of a proposal to use part of its idle raised funds for cash management, with a limit not exceeding 80 million RMB [2] - The decision was made during the 15th meeting of the second board of directors' audit committee and the 17th board meeting held on August 8, 2025 [2] - The usage period for the funds is set for 12 months from the date of board approval, allowing for rolling use within the specified limit and timeframe [2]

Group 1 - The company announced the use of up to RMB 20,000 million of idle raised funds for cash management, ensuring that it does not affect the progress of investment projects and effectively controls risks [1] - On July 1, 2025, the company used RMB 5,000 million of idle funds to purchase structured deposits from China Merchants Bank, with an expected annual yield of 1%-1.65%, resulting in an actual income of RMB 67,808 [1] - As of the announcement date, the company has redeemed the principal and income from the cash management products, with the income transferred to the special account for raised funds [1] Group 2 - The remaining balance of idle raised funds for cash management that has not matured is RMB 7,000 million, which is within the authorized amount and investment period set by the shareholders' meeting [1]

（文章来源：证券日报） 证券日报网讯 8月8日晚间，中集车辆发布公告称，公司于2025年8月8日召开了第三届董事会2025年第 五次会议及第三届监事会2025年第四次会议，审议通过了《关于使用部分A股闲置募集资金进行现金管 理的议案》。公司及子公司拟使用部分A股闲置募集资金人民币不超过63，000.00万元（含本数）进行 现金管理，单笔投资产品期限不超过12个月，使用期限为自公司董事会审议通过之日起生效，不超过12 个月。在上述额度及使用期限范围内，资金可循环滚动使用。 ...

Summary of Key Points Core Viewpoint - The company, Shanghai Medicy Bio-pharmaceutical Co., Ltd., is utilizing part of its idle raised funds for cash management to enhance fund efficiency and generate additional income while ensuring the safety of the funds and not affecting the ongoing investment projects [1][8]. Group 1: Fundraising Overview - The total amount raised by the company as of August 4, 2023, is RMB 1 billion, with a net amount of RMB 985.29 million after deducting underwriting fees [1]. - The funds are stored in a special account, and a tripartite agreement has been signed to regulate the management of these funds [2]. Group 2: Investment Project Details - The net amount raised will be allocated to specific projects, including the establishment of a biopharmaceutical innovation industrial base and laboratory expansion for drug discovery and pharmaceutical research [2]. - The total planned investment for these projects is RMB 2.176 billion, with the adjusted amount from the raised funds being RMB 216 million [2]. Group 3: Cash Management Strategy - The company plans to use up to RMB 400 million of the temporarily idle funds for cash management, ensuring that this does not impact the ongoing projects [4][7]. - The cash management products will include safe and liquid investments such as principal-protected wealth management products, structured deposits, and time deposits [4][6]. Group 4: Decision-Making and Oversight - The board of directors has authorized the management to make investment decisions within the set limits and timeframes, with the finance department responsible for implementation [4][6]. - The company will adhere to disclosure obligations and ensure that the cash management does not alter the intended use of the raised funds [5][8]. Group 5: Monitoring and Compliance - The supervisory board supports the cash management initiative, stating it aligns with regulations and benefits the company and shareholders [7]. - The sponsor institution has confirmed that the cash management plan complies with relevant regulations and does not affect the normal execution of investment projects [8].

国泰海通证券股份有限公司 关于欧派家居集团股份有限公司 使用闲置募集资金进行现金管理的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 欧派家居集团股份有限公司（以下简称"欧派家居"或"公司"）2022 年公开 发行可转换公司债券的保荐机构，根据《证券发行上市保荐业务管理办法》《上 市公司募集资金监管规则》《上海证券交易所股票上市规则》《上海证券交易所 上市公司自律监管指引第 1 号——规范运作》《上海证券交易所上市公司自律监 管指引第 11 号——持续督导》等有关规定，对欧派家居拟使用 2022 年公开发 行可转换公司债券闲置募集资金进行现金管理的事项进行了审慎核查，具体核查 情况如下： 一、投资情况概述 （一）投资目的 为提高募集资金使用效率，在确保不改变募集资金用途且不影响募集资金投 资项目正常运行的情况下，公司已于 2024 年 7 月 25 日召开了第四届董事会第 十六次会议和第四届监事会第十一次会议，审议通过了《关于使用闲置募集资金 进行现金管理的议案》，批准公司使用总额度不超过人民币 5 亿元的暂时闲置募 集资金适时进行现金管理，有效期自 2024 年 8 月 19 ...

关于上海宣泰医药科技股份有限公司 使用部分闲置募集资金进行现金管理的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 上海宣泰医药科技股份有限公司（以下简称"宣泰医药"或"公司"）首次公开 发行股票并上市持续督导保荐机构，根据《证券发行上市保荐业务管理办法》 国泰海通证券股份有限公司 《上 市公司募集资金监管规则》《上海证券交易所科创板股票上市规则》《上海证券 交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关规定，对公司 使用部分闲置募集资金（含超募资金）进行现金管理的事项进行了核查，具体情 况如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意上海宣泰医药科技股份有限公司首 次公开发行股票注册的批复》（证监许可[2022]1383 号），公司获准向社会公开 发行人民币普通股（A）股 45,340,000.00 股，发行价格为 9.37 元/股，募集资金 总额为人民币 42,483.58 万元，扣除与发行相关的费用（不含增值税）人民币 上述资金到位情况经上会会计师事务所（特殊普通合伙）审验，并出具上会 师报字(2022)第 9072 号《验资报告》。20 ...

证券代码：600184 股票简称：光电股份 编号：临 2025-31 北方光电股份有限公司 第七届监事会第十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 北方光电股份有限公司第七届监事会第十一次会议通知于2025年8月 日以通讯表决方式召开，应表决监事3人，实际表决监事3人。会议的召开 符合《公司法》和公司《章程》的规定。监事会经过审议，会议作出如下 决议： 审议通过《关于使用暂时闲置募集资金进行现金管理的议案》 监事会认为，公司使用暂时闲置募集资金进行现金管理，相关决策程 序符合相关规定，有利于提高闲置募集资金的存放收益，不会影响募投项 目建设和募集资金正常使用，符合公司和全体股东的利益，不存在损害公 司及全体股东，特别是中小股东的利益的情形。同意公司使用暂时闲置募 集资金进行现金管理。 表决结果：3票同意，0票反对，0票弃权。 特此公告。 北方光电股份有限公司监事会 二〇二五年八月八日 ...

证券代码：603517 证券简称：绝味食品 公告编号：2025-064 绝味食品股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ?委托理财受托方：中国光大银行股份有限公司 ?本次委托理财金额：1.80亿元 ?产品名称：2025年挂钩汇率对公结构性存款定制第八期产品78 ?履行的审议程序：绝味食品股份有限公司（以下简称"公司"）于2025年4 月9日召开第六届董事会第二次会议和第五届监事会第二十三次会议，2025年5 月9日召开公司2024年度股东会，审议通过了《关于使用部分暂时闲置募集资金 进行现金管理的议案》，同意公司全资子公司合计使用最高额度不超过人民币7 亿元（含7亿元）的暂时闲置募集资金进行现金管理，用于购买安全性高、流动 性好的结构化存款或稳健型短期理财产品，投资期限为自公司2024年度股东会审 议通过之日起12个月，在上述额度及期限内，可滚动使用。公司监事会和保荐机 构对该议案发表了同意意见。具体内容详见公司于2025年4月10日披露的《绝味 食品关于使用部分暂时闲置募集资金进行现金管 ...

Core Viewpoint - The company plans to utilize part of its temporarily idle raised funds for cash management, ensuring that it does not affect the progress of fundraising investment projects or the company's normal operations, with a maximum amount of RMB 450 million allocated for this purpose [1][4][8] Fundraising Basic Situation - The company raised a total of RMB 1,007.745 million through the issuance of 26.45 million shares at a price of RMB 38.10 per share, with a net amount of RMB 936.030479 million after deducting issuance costs [1][2] Fundraising Usage Situation - The adjusted fundraising usage plan includes investments in the construction of facilities for the production of 5 million injection-use paclitaxel polymer micelles, clinical research for expanded indications, marketing network construction, and supplementary working capital [2][5] Cash Management Plan - The company intends to invest the idle funds in low-risk, high-liquidity products that meet capital preservation requirements, such as guaranteed financial products, structured deposits, and large certificates of deposit, with a usage period not exceeding 12 months [4][5][7] Impact on Company Operations - The cash management plan is expected to enhance the efficiency of fund usage without impacting the normal operations of the company or its fundraising investment projects, ultimately benefiting shareholders by increasing investment returns [5][6] Decision-Making Process - The board of directors approved the cash management plan on August 7, 2025, ensuring compliance with relevant regulations and safeguarding shareholder interests [6][8]